Review anchor
Glutamate receptor ionotropic, NMDA 2A
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
Evidence Snapshot
Glutamate receptor ionotropic, NMDA 2A
CHEMBL310
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate receptor ionotropic, NMDA 2A as ChEMBL target CHEMBL310, mapped to UniProt Q00959. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL310
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q00959
Glutamate receptor ionotropic, NMDA 2A
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Glutamate receptor ionotropic, NMDA 2A matters
Glutamate receptor ionotropic, NMDA 2A is reviewed as Glutamate receptor ionotropic, NMDA 2A (UniProt Q00959); the current evidence base includes 0 approved drugs, 131 compounds, and 29 assays, with lead potency reaching pChEMBL 7.5.
Protein context
Glutamate receptor ionotropic, NMDA 2A
Glutamate receptor ionotropic, NMDA 2A Sequence length is 1464 aa.
Review this target as Glutamate receptor ionotropic, NMDA 2A, mapped to UniProt Q00959. Sequence length is 1464 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q00959
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 131 compounds, and 29 assays for this target. The dominant activity type is IC50. CHEMBL29811 is the current potency anchor at pChEMBL 7.5.
Use CHEMBL29811 as the tractability anchor when discussing potency (pChEMBL 7.5).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 7.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Glutamate receptor ionotropic, NMDA 2A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q00959, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
131
Total Compounds
29
Total Assays
0
Approved Drugs
IC50: 65.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL29811
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL39664
|
7.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL431029
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL2178919
|
6.8 | IC50 | — |
|
|
No preferred name
CHEMBL1098240
|
6.8 | IC50 | — |
Source Header